Lalita Prasad-Reddy|Diana Isaacs
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Chicago State University|Chicago State University
prevalence type 2 diabetes increasing astounding rate many agents used treat type 2 diabetes undesirable adverse effects hypoglycemia weight gain glucagonlike peptide1 glp1 receptor agonists represent unique approach treatment diabetes benefits extending outside glucose control including positive effects weight blood pressure cholesterol levels betacell function mimic effects incretin hormone glp1 released intestine response food intake effects include increasing insulin secretion decreasing glucagon release increasing satiety slowing gastric emptying currently four approved glp1 receptor agonists united states exenatide liraglutide albiglutide dulaglutide fifth agent lixisenatide available europe important pharmacodynamic pharmacokinetic clinical differences agent common adverse effects seen glp1 therapy include nausea vomiting injectionsite reactions warnings precautions include pancreatitis thyroid cell carcinomas glp1 receptor agonists innovative effective option improve blood glucose control potential benefits preserving betacell function weight loss increasing insulin sensitivity onceweekly formulations may also improve patient adherence overall effective agents patients type 2 diabetes either uncontrolled metformin intolerant metformin